Assertio Therapeutics (ASRT) Misses Q4 EPS by 99c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall St set to fall at open as yields and oil rebound; Fed minutes in focus
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts ASRT Hot Sheet
Join SI Premium – FREE
Assertio Therapeutics (NASDAQ: ASRT) reported Q4 EPS of ($1.06), $0.99 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $13.54 million versus the consensus estimate of $28.36 million.
For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Yorkville Ives Reiterates Outperform Rating on SpaceX (SPCX)
- Yorkville Ives Starts Meta Platforms Inc. (META) at Outperform
- Yorkville Ives Starts GameStop (GME) at Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
